Clinical Trial Update: Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is being planned to test whether inhibiting Factor XI can reduce adverse vascular events in adults with Peripheral Artery Disease; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Peripheral Artery Disease (PAD) | Phase 3 | Status: NOT_YET_RECRUITING